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ABSTRACT 
 
Small interfering RNA (siRNA)-based technology is playing a pivotal role in understanding gene function.  
Huge siRNA libraries coupled to high-content screening are being applied to decipher molecular circuitries, 
as well as to identify novel therapeutic targets. Further, the technology is finding its way towards therapeutic 
applications. In the midst of all this excitement, the siRNA technology is faced with challenges, arising 
mostly from siRNAs being a nucleic acid molecule, and also from the baggage it inherits from the RNA in-
terference (RNAi) pathway, which is critical to the function of siRNAs. 
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INTRODUCTION 
 
Within a short span of time after its discovery (Caplen et 
al, 2001; Elbashir et al, 2001), siRNAs have become the 
key technology  in the application  of reverse  genetics to 
understand gene function by eliminating or reducing the 
expression of a gene of interest. The technique is easy to 
use, relatively specific, and highly-efficacious with broad 
applicability across multiple cell types in human. siRNAs 
exert their function by high jacking an evolutionary con-
served cellular process called RNA interference (RNAi). 
RNAi, thought to have been evolved as a defence mecha-
nism  in  primitive  organisms  (Lu  et  al,  2005;  Plasterk, 
2002; Wilkins et al, 2005; Zamore, 2002), plays a pivotal 
role in gene regulation in both plants and animals by using 
an endogenous, non-coding small RNA species called Mi-
croRNAs  (miRNA).  At  a  fundamental  level,  RNAi is  a 
sophisticated antisense mechanism (Figure 1) that captures 
one strand from a double stranded miRNA (or siRNA) into 
an  effecter  protein  complex  called  RISC  (RNA-induced 
silencing complex). The RISC complex uses the captured 
strand  as  a  ‘guide’  to  target  complementary  sequences 
within an mRNA. While the target sites for miRNAs are 
typically  located  within  the  3’-untranslated  regions  (3’-
UTRs), siRNAs are designed to target anywhere within an 
mRNA. The fate of the mRNA is dictated by the degree of 
complimentarity between the guide strand of the siRNA 
duplex and the target region; if the complimentarity is per-
fect or near perfect (as in the case of siRNAs) the endonu-
clease activity within the RISC cleaves the target mRNA; 
however, if the complimentarity is imperfect (as with most 
miRNAs),  a  suppression  of  protein  translation  occurs 
through a mechanism that is poorly understood even to-
date. Both mechanisms down regulate protein expression, 
but the action of the one that utilizes incomplete base pair-
ing is  reversible,  as  it  does  not  permanently  reduce  the 
level of the target mRNA. 
 
In  this  review,  keeping  in  mind  the  potential  of  siRNA 
technology to become a therapeutic modality, I have made 
an attempt to highlight challenges that the technology is 
currently facing. These challenges are stemming from the 
ability of the exogenous siRNA to hijack a natural molecu-
lar pathway, evolved and optimized mostly for miRNAs, 
and siRNA being a nucleic acid molecule. As challenges 
bring new opportunities, I have included recent advance-
ments in the field to bring the siRNA technology a step 
forward in realizing its therapeutic potential. 
 
CHALLENGES  ARISING  FROM  THE  RNAi 
PATHWAY 
 
An exogenous siRNA is a molecular mimicry of the en-
zyme product of natural double-stranded RNA that enters  
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RNAi pathway. It is also designed to have a full compli-
mentarity to the target site of interest to ensure long-term 
gene silencing through mRNA cleavage. Early successes 
of gene silencing by siRNAs based on simple design rules 
(Elbashir  et  al,  2002)  lost  consistency  when  applied  to 
diverse gene sets (Aza-Blanc et al, 2003). Later, some un-
derstanding of the mechanism of the RISC assembly im-
proved siRNA design (Khvorova et al, 2003; Schwarz et 
al,  2003).  In  the  natural  RNAi  pathway,  in  almost  all 
cases, only the miRNA strands (miRs), but not their com-
pliments  (miR*s)  are  incorporated  into  the  RISC.  The 
analysis of miRNA duplexes revealed an asymmetry at the 
two ends dictated by the base pairing stability (Khvorova 
et al, 2003). Analogous asymmetry with less stable 5’end 
of the antisense strand compared the 5’end of the sense 
strand was also noticed among highly-functional siRNAs 
(Khvorova et al, 2003; Schwarz et al, 2003). This differen-
tial thermodynamic stability of the two termini of an RNA 
duplex  dictates  which  strand  gets  incorporated  into  the 
RISC. Hence, by design, the preferred antisense strand can 
be directed to populate the RISC, ensuring efficient degra-
dation of target mRNA in the absence of potential off tar-
get silencing mediated by the sense strand. While this dis-
covery made a significant advance towards the improve-
ment of siRNA design, specific base preferences at certain 
locations within an siRNA duplex have also been noted 
(Reynolds et al, 2004), and incorporated into design algo-
rithms. A phosphate group at the 5’end of the antisense 
strand is required for efficient RNAi (Nykanen et al, 2001; 
Martinez et al, 2003). The core activities of the RISC ap-
pear  to  reside  within  a  complex  containing  a  single-
stranded guide RNA and an Argonaute family protein (Liu 
et al, 2004; Meister et al, 2004). The crystal structures of 
the  PIWI  domain  of  an  Argonaute  protein  revealed  the 
existence of a highly basic pocket chelated with a metal 
ion to capture the charged 5’phosphate group of the guide 
strand (Ma et al, 2005; Parker et al, 2004). This interaction 
may facilitate the positioning of the guide strand for effec-
tive target cleavage by “slicer” endonuclease activity re-
siding in the human Argonaute2 (Ago2) protein, as well as 
to increase the half-life of the RISC. Hence, the elimina-
tion  of  the  5’phosphate  group  in  the  sense  strand  by 
chemical modification would exclude the participation of 
the sense strand in unintended gene silencing.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. An overview of the RNAi pathway that designer siRNAs used for gene silencing. Synthetic siRNAs introduced to a cell are 
expected to take part (red arrows) in the natural RNAi process evolved for miRNA function (as indicated in green arrows). Out of the 
three pathways outlined for gene silencing, the transcriptional silencing by RISC programmed by either miRNA or siRNA in verte-
brates is not completely understood no it is validated beyond doubts, hence noted with (?). 
CH
3
CH
3
mRNA cleavage AAAA
AAAA
Nucleus
Cytoplasm
Transcriptional Inhibition
miRNA gene
Genomic DNA
Pol II transcription
Pri-miRNA
Drosha
Exportin 5
Dicer
Pre-miRNA
miRNA
RISC SiRNA
Cell membrane
RISC
RISC
RISC/RITS
Translational Inhibition
?
?
?
CH
3 CH
3
CH
3 CH
3
mRNA cleavage AAAA
AAAA
Nucleus
Cytoplasm
Transcriptional Inhibition
miRNA gene
Genomic DNA
Pol II transcription
Pri-miRNA
Drosha
Exportin 5
Dicer
Pre-miRNA
miRNA
RISC SiRNA
Cell membrane
RISC
RISC
RISC/RITS
Translational Inhibition
?
?
? 
© Jayasena | Journal of RNAi and Gene Silencing | February 2006 | Vol 2, No 1 | 109-117 | OPEN ACCESS 
111 
A multiple number of algorithms have been developed for 
picking effective siRNAs (Gong and Ferrell, 2004; Rey-
nolds et al, 2004; Snove et al, 2004), including a pattern-
learning approach based on neural networks (Huesken et 
al,  2005).  To  improve  specificity,  these  algorithms  per-
form  in  silico  screening  to  eliminate  candidate  siRNAs 
with near perfect pairing to unintended genes in the human 
(target)  genome. In addition to the focus  on the siRNA 
duplex, the attention to the target mRNA accessibility has 
also been shown to be important for efficient gene silenc-
ing (Bohula et al, 2003; Heale et al, 2005; Overhoff et al, 
2005;  Schubert  et  al,  2005).  An  empirical  approach  to 
probe accessible sites within a target mRNA (Heale et al, 
2005) didn’t gain a widespread use due to laborious nature 
of  the  technique,  especially  in  high  throughput  applica-
tions.  However,  accessibility  of  target  sites  needs  to  be 
addressed  to  further  optimize  siRNA  design  rules.  One 
approach would be to screen regions of potential mRNA 
target  sites  by  an  RNA  folding  program  such  as  mfold 
(Zuker, 2003) or sfold (Ding et al, 2004) to eliminate sites 
within tightly folded RNA motifs that may resist targeting 
by the RISC. This may not be 100% effective in eliminat-
ing all inaccessible sites due to either the potential long-
range  interactions  within  long  mRNA  sequences  or  se-
questering  of  target  sites  upon  interaction  with  RNA-
binding proteins or both. 
 
A potential pitfall in current siRNA designs is the diffi-
culty in weeding out sequence-specific off-targets result-
ing  from  the  pairing  rules  identified  for  miRNA/target 
recognition. The 5’seed region that  defines 2-7 nts  of a 
miRNA mediates target recognition (Lewis et al, 2003), 
allowing  multiple  targets  to  be  regulated  by  a  single 
miRNA. This promiscuous target recognition characteris-
tic of miRNAs has a toll on siRNA applications. Microar-
ray  analysis  indicated  that  siRNAs  could  mediate  gene 
silencing  of  unintended  targets  through  their  5’regions 
(Jackson et al, 2003). In general, gene silencing mediated 
by siRNA through miRNA mechanism is not transparent 
at  the  mRNA  level,  but  detectable  at  the  protein  level.  
This phenomenon, already noticed in siRNA applications 
(Jackson et al, 2003; Saxena et al, 2003), would become 
more  wide-spread as  investigators  start  looking  into  the 
global  changes  of  the  proteome  affected  by  siRNA  ex-
periments  (Scacheri  et  al,  2004)  or  the  use  of  a  large 
siRNA libraries on a single gene (Lin et al, 2005). It is 
needless  to  emphasize  the  value  of  siRNA  libraries  de-
signed to knockdown many gene families, and their appli-
cations  in  identifying  novel  gene  targets  for  therapeutic 
interventions,  as  well  as  in  deciphering  molecular  path-
ways. However, a caution must be exercised in interpret-
ing the results derived from genome wide or gene family-
wide siRNA screening in the absence of extensive valida-
tion  in  subsequent  experiments  to  rule  out  potential  off 
targets  leading  to  inadvertent  erroneous  conclusions.  
Keeping the concentration of siRNA at relatively low, yet 
effective,  level  is  important  to  avoid  non-specific  gene 
regulation  mediated  by  high  concentrations  of  siRNA 
(Persengiev et al,  2004; Semizarov et al,  2003). On the 
other hand, the elimination of the off-target silencing me-
diated by the 5’seed pairing is extremely challenging, and 
most  siRNAs  will  have  a  number  of  unintended  targets 
affected by 5’seed pairing, as a six contiguous string of 
bases  occurs  quite frequently  within  a  genome  (once  in 
every 4 kb sequence). 
 
More than one siRNA to a given target is commonly used 
in discovery research to ensure a single phenotype result-
ing from on-target gene silencing by most siRNAs used. 
“Multiple siRNAs per target” approach is acceptable for 
discovery research but fails in potential therapeutic appli-
cations.  Ideally,  therapeutic  applications  demand  on-
target mechanism with little or no off-target silencing – a 
formidable task.  However, if the number of potential off-
targets can be reduced to a minimum level, then therapeu-
tic  siRNAs  may  not  be  all  that  different  from  a  small 
molecule  kinase  inhibitor  that  inhibits  multiple  kinases. 
The latter class of  molecules is  beginning  to enter into 
clinical trials. Nonetheless, further refinement of design 
algorithms  would  be  warranted  for  siRNAs  especially 
aimed  for  therapeutic  developments.  A  significant  pro-
gress has been made in developing algorithms for predict-
ing miRNA targets based on the 5’seed pairing (John et 
al, 2004; Kiriakidou et al, 2004; Stark et al, 2003), the 
same exact mechanism that renders siRNAs for off-target 
recognition. In the future, it is expected to merge miRNA 
target  prediction  algorithms  with  those  developed  for 
siRNA design to eliminate candidate siRNAs with poten-
tial  off  target  gene  silencing  through  the  undesirable 
miRNA-related mechanism. 
 
Recently, another twist to the already complex subject of 
off target gene silencing was introduced by demonstrating 
transcriptional gene silencing by siRNAs (Kawasaki and 
Taira, 2004; Morris et al, 2004). The siRNA-guided RISC 
apparently silenced the transcription of specific chromatin 
regions consisting of homologous DNA by recruiting fac-
tors  that  methylate  genomic  DNA.  Both  siRNA  and 
miRNA guided RISC have been shown to be present and 
active  in  both  cytoplasmic  and  nuclear  compartments 
(Robb et al, 2005). Whether the partitioning of the RISC 
between nucleus and cytoplasm is a consequence of the 
degradation of nuclear membrane during cell division or 
through  an  active  transport  mechanism  is  not  currently 
understood. In spite of some experimental evidence, it is 
worth noting that the entire phenomenon of transcriptional 
silencing by RISC (or RITS: RNA-induced transcriptional 
silencing) in vertebrates is controversial. If this phenome-
non is proven to exist, then strategies to keep this activity 
at bay would be important for siRNA applications. 
 
CHALLENGES FROM SIRNA BEING A NUCLEIC 
ACID MOLECULE 
 
Elicitation of immune response in mammals 
Microbes trigger innate immune response in mammals by 
activating  Toll-like  receptors  (TLR).  Among  others,  the 
molecular  species  that  are  sensed  as  non-self  by  TLRs 
include ssRNA, dsRNA and CpG motifs in DNA derived 
from viruses, bacteria and fungi. The innate immune re-
sponse triggered by TLRs includes the activation of Type 
1  Interferon  (IFN)  system.  In addition,  the  dsRNA  also 
triggers other antiviral responses comprising of the activa-
tion of PKR, Oligoadenylate synthase and RNase L (Katze 
et al, 2002). However, in general, siRNAs tend to escape 
the activation of antiviral response that is commonly trig- 
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gered  by  dsRNA  molecules  longer  than  the  canonical 
siRNAs. This view held initially on siRNA (Elbashir et al, 
2001) has recently been challenged, as some siRNA mole-
cules  elicit  interferon  response  in  cultured  cells  and  in 
animals (Bridge et al, 2003; Judge et al, 2005; Kariko et al, 
2004; Kim et al, 2004; Sledz et al, 2003). Recently, spe-
cific molecular footprints within siRNAs that could stimu-
late undesirable  immune response  have  been  discovered 
(Hornung et al,  2005; Judge et al,  2005). These studies 
identified two different sequence elements (5’-UGUGU-3’ 
and 5’-GUCCUUCAA-3’) with a common function: exert-
ing immune response when delivered using cationic lipids, 
which  directs  siRNAs to  the  endosomal  pathway  where 
they  encounter  TLRs.  The  elimination  of  such  putative 
immune stimulatory elements (ISEs) from an siRNA se-
quence reduced the immune response when delivered in 
liposome formulations both in vitro and in vivo settings.  
Surprisingly, the siRNA molecules that lacked the known 
putative ISEs were also capable of eliciting immune re-
sponse in mice (Morrissey et al, 2005), suggesting the pos-
sible existence of hitherto unknown ISEs in siRNA. Most 
importantly, chemical modifications introduced at differ-
ent positions of siRNAs led to a marked reduction of in-
flammatory cytokines induced in mice. This suggests that 
the chemical modification of siRNAs may be a potential 
approach  for  evading  mammalian  immune  surveillance 
evolved to sense unmodified natural nucleic acids. Inter-
estingly,  the  aforementioned  two  ISEs  were  identified 
from studies on a rather limited sequence space. It is likely 
that new ISEs in siRNA would be identified in the future 
by using random sequence libraries of siRNAs exhausting 
all possible nucleotide combinations. The elimination  of 
all  possible  potential  ISEs  in  combination  with  specific 
chemical  modifications  would expect  to  provide cleaner 
siRNA molecules for future therapeutic applications.   
 
In vivo systemic delivery – another major challenge to 
be defeated 
In spite of certain shortcomings associated with the tech-
nology, siRNA has become the laboratory workhorse for 
elucidating  gene  function.  Yet  the  technology  failed  to 
penetrate into therapeutic arena for the foremost challenge 
in developing effective strategies for in vivo delivery. The 
initial  proof-of-principal  experiments  demonstrating  in 
vivo efficacy in mice were based on an unorthodox deliv-
ery approach of high-pressure tail vein injection (HTVI), 
a  method  inappropriate  for  human.  Recently,  several 
groups have devised different approaches for systemic in 
vivo  delivery  of  siRNAs  (Figure  2).  Such  approaches 
would  provide  a  foundation  on  which  further  advance-
ments to be made in the future to make siRNA therapeu-
tics a reality.  HTVI delivery of naked siRNAs did not 
show  in  vivo  immune  response  in  mice  (Heidel  et  al, 
2004),  but  siRNAs  formulated  into  cationic  lipids  and 
delivered by low pressure IV did trigger an in vivo im-
mune  response  (Judge  et  al,  2005),  suggesting  siRNAs 
complexed  with  lipids  traffic  through  cellular  compart-
ments involved in immune activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Different approaches used for in vivo delivery of siRNAs. Approaches I and III are exclusively based on chemically syn-
thesized molecules. Whereas the approach II relies on synthetic siRNAs and biologically produced hybrid proteins. This approach 
could be adapted to deliver siRNAs into specific cell types by exploiting cell surface receptors unique to each cell type.
+
+ +
+
+
+
+
+
+
+
?
- Cationic lipid
- fusogenic lipid
- PEG lipid
- Lipophelic moiety
- Protamine-Fab fusion
-Cell surface
receptor
Endosome
I
I I I
II II II
III III
+
+ +
+ +
+ +
+
+
+
+
+
+
+
+
+
+
+
+
+
?
- Cationic lipid
- fusogenic lipid
- PEG lipid
- Lipophelic moiety
- Protamine-Fab fusion
-Cell surface
receptor
Endosome
I
I I I
II II II
III III 
© Jayasena | Journal of RNAi and Gene Silencing | February 2006 | Vol 2, No 1 | 109-117 | OPEN ACCESS 
113 
The direct conjugation of cholesterol to the 3’end of the 
sense strand has improved in vivo delivery of chemically 
modified  naked  siRNAs  by  intravenous  injection 
(Soutschek et al, 2004). Cholesterol-conjugated, chemi-
cally  modified  siRNAs  against  the  liver  target  Apo-B 
showed reduction of the cognate protein level in mouse 
plasma by 30-70% (depending on the siRNA used), when 
administered  at  a  relatively  high  dose  (50  mg/kg)  for 
three consecutive days and assayed a day later. Choles-
terol conjugation appears to facilitate intracellular uptake 
of siRNA in tissue culture in the absence of a lipid-based 
transfection  agent.  When  delivered  in  vivo,  it  signifi-
cantly  enhanced  pharmacokinetics  parameters,  slowing 
down the plasma clearance presumably upon binding to 
serum proteins. 
 
A novel approach (Song et al, 2005) took the advantage 
of a chimeric molecule made up of two molecular mod-
ules; one for cellular homing, provided by heavy-chain 
antibody fragment (Fab), and the other for nucleic acid 
loading, provided by a positively charged peptide derived 
from basic protein protamine that condenses nucleic ac-
ids. This approach also allowed for the delivery of naked 
siRNAs avoiding the use of cationic lipid formulations. 
Using  an  anti-HIV-1  envelope  Fab  fused  to  protamine 
peptide showed uptake of fluorescein-tagged siRNA spe-
cifically into HIV-1 envelope expressing cells in culture. 
The use of anti-gag siRNA in this system showed inhibi-
tion of viral replication in HIV-infected primary T-cells, 
cells that generally resist transfection even with widely 
used  lipid  formulations.  The  cell-specific  delivery  was 
extended  to  in vivo  settings  using a  model  in which  a 
melanoma cell line engineered to express HIV-1 enve-
lope protein implanted into the flanks of mice. The ani-
mals were challenged with a cocktail of siRNAs against 
c-myc, MDM2 and VEGF genes loaded onto anti-HIV-1-
Fab-Protamine  fusion  construct  by  either  intratumor  or 
intravenous injections on 0, 1 and 3 days after implanting 
tumor cells (approximately 4 mg/kg of siRNA per injec-
tion). Intra-tumoral delivery showed higher efficacy than 
the intravenous delivery in reducing tumor volume up to 
9 days after treatment.  These preliminary results are en-
couraging  and  warrant  further  investigations  in  robust 
animal models in which the regression of already estab-
lished tumors could be addressed. To allow such studies 
the authors have taken initial steps in making a fusion 
construct of anti-ErbB2-Fab-Protamine to target ErbB2-
expressing  breast  tumors.    Again,  encouraging  results 
showing specific targeting of ErbB2-expressing MCSF7 
cells were obtained in culture.  Though this is an interest-
ing approach for in vivo delivery  of siRNA, additional 
research  and  improvements  are  necessary  before  the 
technique is embraced widely.  Some of these issues may 
include  improving  the  payload  capacity  of  siRNAs,  as 
each  complex  tend  to  carry  approximately  six  siRNA 
molecules in the current format; demonstrating specific 
delivery into a wider tissue/cell types using a variety of 
receptor-based affinity tags; evaluating pharmacokinetics 
and  dynamics  of  these  complexes,  shelf  life  and  their 
overall stability, as well as possible unanticipated toxic 
effects such as immunogenecity; and finally, the produc-
tion cost associated with a protein-RNA complex of this 
nature for therapeutic intervention in human. 
An integrated approach that incorporated refined siRNA 
picking  that  avoided  potential  ISEs,  chemical  modifica-
tions  that  enhanced  stability  and  programmed  RISC  as-
sembly, and formulation into specific liposome  particles 
comprising  of  cationic,  fusogenic  lipids and  an  external 
coating  with  a  hydrophilic  polyetheleneglycol  has  been 
recently reported (Morrissey et al, 2005) and showed no-
table improvement in possible therapeutic delivery. In this 
example,  antiviral  siRNAs  carrying  positional  chemical 
modifications,  encapsulated  into  specialized  liposomal 
particles demonstrated dose-dependent reduction of viral 
DNA (> 1 log) seven days after the last dose of IV deliv-
ery (3 or 0.3 mg/kg for 3 consecutive days) in a mouse 
model of HBV replication. Based on highly-effective gene 
silencing at <10 nM siRNA in tissue culture experiments, 
this is a reasonable dose for in vivo efficacy. The mouse 
liver  model  of  HBV  is  established  by  HTVI  of  a HBV 
vector  6  days  prior  to  the  delivery  of  encapsulated 
siRNAs, a potential caveat associated with the interpreta-
tion of the delivery efficacy into an already compromised 
mouse  liver.  This  has  been  somewhat  addressed  by  ex-
tending weekly maintenance dose up to 6 weeks after the 
initial dose, and still showing significant reduction of se-
rum HBV DNA titer. Further investigations into a possi-
bility of silencing an endogenous gene in mouse liver in 
the absence of a prior HTVI would be useful in determin-
ing the full potential of this approach. 
 
While broad therapeutic applications prefer nonviral deliv-
ery of siRNAs to avoid obvious complications associated 
with viral delivery into human, in vitro applications cer-
tainly  benefited  from  the  development  of  plasmid-based 
vectors that are designed to deliver siRNA through shRNA 
(small hairpin RNA in which the siRNA forms the base-
paired stem). The initial excitement in siRNA technology 
led to discover ways to deliver siRNA into cells using ex-
pression  vectors.  Based  on  the  small  size  of  shRNAs, 
RNA  polymerase  III  (pol  III)-based  expression  vectors 
were developed (Paddison et al, 2004) (Tuschl, 2002), as 
promoters  that  recruit  pol  III  efficiently  transcribe  short 
non-coding RNA species like tRNAs and small nucleolar 
RNAs. The development of pol III-based shRNA expres-
sion systems was greeted with much enthusiasm, as they 
were  readily  adapted  to  viral  delivery  systems  that  ex-
panded the number of cell types amenable for gene silenc-
ing.  Conditional  or  regulated  gene  silencing  provides  a 
window of opportunities to study genes that can be diffi-
cult to address otherwise, including those that regulate cell 
cycle,  apoptosis  and proliferation.  Further,  long-term  si-
lencing of genes may lead to conditions that are nonphysi-
ological. Pol II-based promoters have already been engi-
neered to provide conditional gene expression in response 
to small molecules such as tetracycline or ecdysone. To 
afford  conditional  shRNA  expression,  inducible  pol  III-
based systems were subsequently developed (Czauderna et 
al, 2003; Gupta et al, 2004; van de Wetering et al, 2003). 
 
All this development took place before the elucidation of 
miRNA biogenesis to the current understanding. Interest-
ingly,  miRNAs  are  encoded  in  long  transcripts  derived 
from pol II transcription and efficiently processed into a 
small fragment of ~22-nt prior to get incorporated into the 
RISC (reviewed in Bartel, 2004; Kim, 2005). Furthermore,  
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miRNAs can function as siRNAs and vice versa (Doench 
et al, 2003; Zeng et al, 2002; Zeng et al, 2003). Signals 
that  are  required  for  efficient  miRNA  processing  have 
been shown to reside within less than 40 nts either side of 
a miRNA precursor (Chen et al, 2004) and would be im-
portant  for  efficient  gene  silencing  when  shRNA  se-
quences  were  embedded  in  place  of  a  miRNA.  Some 
miRNAs are naturally expressed in a single transcript in a 
multicystronic  fashion.  Embedding  shRNAs  designed  to 
silence  multiple  genes  within  a  single  pol  II  transcript 
would allow concurrent silencing of multiple genes. Previ-
ously developed regulatable pol II promoters could now be 
adaptable for conditional gene silencing using transcripts 
based  on  miRNA  frameworks  (Stegmeier  et  al,  2005), 
leaving behind pol III-based expression systems developed 
exclusively for shRNA expression. In a way, the develop-
ment of shRNA expression vectors have come a full circle. 
 
REALIZING  THERAPEUTIC  POTENTIAL  OF 
siRNA       
 
The full potential of siRNA therapeutics would be realized 
only after a solution to an effective intracellular delivery is 
achieved. While systemic applications of siRNA to combat 
multiple disease areas wait for such a breakthrough, appli-
cations in which local delivery of siRNA (or shRNA) into 
restricted tissue compartments have advanced much closer 
to human therapeutics. Clinical trials are currently under-
way in patients with macular degeneration to control reti-
nal  angiogenesis  by  intraocular  delivery  of  synthetic 
siRNA to VEGF receptor (http://www.sirna.com). A lenti-
viral vector-based delivery of shRNA to control HIV rep-
lication is being  developed as a therapy for AIDS lym-
phoma  patients  (http://www.benitec.com).  Clinical  trials 
will soon be initiated in this patient population by ex-vivo 
transduction of autologous hematopoietic progenitor cells 
with  viral  vectors  carrying  an  arsenal  of  shRNA  con-
structs. The results of these clinical trials would be critical 
for the field of siRNA therapeutics and will pave the way 
for diverse applications in the future.   
  
CONCLUSIONS AND FUTURE PERSPECTIVE  
 
The siRNA technology has already become an indispensable 
tool for understanding the roles of a myriad of genes identi-
fied by recent sequencing efforts of a number of genomes 
including the human. To that end, high-throughput genome 
wide  RNAi  combined  with  high-content  screening  ap-
proaches are already being developed (Brummelkamp et al, 
2003; Wheeler et al, 2005). These efforts will lead to uncover 
novel biological pathways, as well as to identify missing links 
in already known cellular circuitries (MacKeigan et al, 2005; 
Willingham et al, 2004). Further, the indirect impact of this 
powerful  technology  in  developing  novel  therapeutics  will 
soon come into life by identifying and validating novel thera-
peutic targets that has not been able to accomplish so quickly 
by using alternate approaches. Synthetic lethal screening in 
tissue culture is just one such approach with the potential for 
identifying  novel  therapeutic  targets  (Brummelkamp  and 
Bernards, 2003; Wheeler et al, 2004). 
 
However, the technology has failed to deliver its promise 
on siRNA as a broad therapeutic modality for overwhelm-
ing challenge associated with the systemic in vivo delivery 
of nucleic acid molecules, albeit examples of local siRNA 
delivery has reached human clinical trials. This has been 
the case in the past for all other nucleic acids based tech-
nologies,  including  antisense,  ribozymes  and  triplexes. 
Another parallel to antisense technology is the identifica-
tion of immune stimulatory motifs in siRNA sequences, 
similar to those discovered in antisense molecules (Krieg 
et  al,  1995).  However,  various  chemical  modifications 
developed  for  other  nucleic  acids  based  therapeutic  ap-
proaches are beginning to permeate into the siRNA field to 
improve the potential of siRNA therapeutics. In this light, 
a designer therapeutic  siRNA molecule  (Figure 3)  would 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Designer siRNAs for potential therapeutic applications. Initial siRNA sequences identified using improved algorithms are 
further modified to provide various attributes to make them more appealing for therapeutic uses. 
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carry various chemical modifications at defined positions 
for: protection from nucleases and to modulate interactions 
with serum proteins to improve in vivo pharmacokinetics; 
guiding  the  antisense  strand  into  the  RISC  assembly  to 
improve efficacy to lower the therapeutic dose; blocking 
the  sense  strand  participating  in  RNAi  to  eliminate  off 
target  gene  silencing;  eliminating  immune  activation  by 
evading TLRs; attaching other molecular appendages (for 
example, cholesterol) to improve in vivo, as well as tissue-
specific delivery. Some of the chemical modifications can 
be generalized as they can be introduced independent of 
the siRNA sequence, but certain others will be sequence-
specific. The latter class of modifications requires a care-
ful study with each siRNA sequence to identify how ex-
actly the various modifications introduced at each position 
would affect critical parameters like the immune activation 
and RISC assembly. The development of in vitro assays 
that will allow effective screening of a host of chemical 
modifications deemed necessary. A recent report indicat-
ing the successful in vitro reconstitution of the RISC activ-
ity with recombinant hAgo2 (Rivas et al, 2005) would be 
useful in that regard. 
 
Off-target gene silencing, which could be managed for in 
vitro  applications  could  still  be  an  issue  for  therapeutic 
applications,  and  requires  creative  approaches  to  reduce 
the number of potential off targets.  Future siRNA design 
algorithms (Figure 4) that incorporate steps to eliminate 
known ISEs as well as the miRNA target prediction algo-
rithms would be of value to significantly reduce the num-
ber of potential off targets for a designer siRNA. In spite 
of all these developments that are important for therapeutic 
applications, the real success of siRNA therapeutics will 
depend on the advancement made on efficient in vivo sys-
temic delivery of siRNA molecules, along with the out-
comes of the ongoing and planned clinical trials. Based on 
already made progress in this area, it is reasonable to an-
ticipate an optimistic future for siRNA therapeutics. 
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Figure 4.  A schematic flow chart of an improved siRNA design algorithm. This proposed approach takes into account of the follow-
ing: 1. Screening for potential target accessibility, 2. Elimination of known immune stimulatory elements (ISEs), 3. Elimination of 
candidate siRNAs that show high number of potential off-target genes by 5’-seed pairing as identified through algorithms developed 
for miRNA target prediction.  * Most of existing siRNA design algorithms include off-target screening by perfect or near perfect 
base pairing.   
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